Phase 1 Trial Evaluating Mrg-106, A Synthetic Inhibitor Of Microrna-155, In Patients With Cutaneous T-Cell Lymphoma (Ctcl).
Francine M. Foss,Christiane Querfeld,Pierluigi Porcu,Youn H. Kim,Theresa Pacheco,Ahmad Halwani,Jennifer DeSimone,Basem M. William,Anita Seto,Judy Ruckman,Michele L Landry,Aimee L. Jackson,Linda A Pestano,Brent A. Dickinson,Mark Sanseverino,David M. Rodman,Paul Rubin,Gilad Shalag Gordon,William Marshall JOURNAL OF CLINICAL ONCOLOGY（2017）
AI 理解论文
溯源树
样例
